pH-sensitive microsphere delivery increases oral bioavailability of calcitonin

Journal of Controlled Release

Volumn 98, Issue 1, 2004, Pages 1-9

  Lamprecht, Alf ^a   Yamamoto, Hiromitsu ^a   Takeuchi, Hirofumi ^a   Kawashima, Yoshiaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Calcitonin; Colon delivery; Eudragit; Microspheres; Oral bioavailability

Indexed keywords

DISSOLUTION; PH EFFECTS; REACTION KINETICS; SOLUTIONS;

MICROSPHERES (MS); ORAL CALCITONIN (CT) ADMINISTRATION; PHARMACOLOGICAL EFFECT;

BIOCHEMICAL ENGINEERING;

CALCITONIN; CARBOXYFLUORESCEIN; DYE; EUDRAGIT; MICROSPHERE; P 4135F; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; EMULSION; MALE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCITONIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; MALE; MICROSPHERES; RATS; RATS, WISTAR;

EID: 3042854242     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.02.001     Document Type: Article

References (32)

1. Patel S., Lyons A.R., Hosking D.J. Drugs used in the treatment of metabolic bone diseases. Drugs. 46:1993;594-617
2. Stevenson J.C., Evans I.M.A. Pharmacology and therapeutic use of calcitonin. Drugs. 21:1981;257-273
3. Huwyler R., Born W., Ohanhaus E.E., Fischer J.A. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am. J. Physiol. 236:1979;E15-E19
4. Hastewell J., Lynch S., Williamson I., Fox R., Mackay M. Absorption of human calcitonin across the rat colon in vivo. Clin. Sci. 82:1992;589-594
5. Milstein S.J., Barantsevitch E.N., Grechanovski V.A., Sarubbi D.J. pH-dependent microspheres from modified soybean protein hydrolysate. J. Microencapsul. 13:1996;651-665
6. Prabhu S., Sullivan J.L., Betageri G.V. Comparative assessment of in vitro release kinetics of calcitonin polypeptide from biodegradable microspheres. Drug Deliv. 9:2002;195-198
7. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 12:1995;101-149
8. Lin S.Y., Ayres J.W. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm. Res. 9:1992;1128-1131
9. Lorenzo-Lamosa M.L., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J. Design of microencapsulated chitosan microspheres for colonic drug delivery. J. Control. Release. 52:1998;109-118
10. Rodriguez M., Vila-Jato J.L., Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J. Control. Release. 55:1998;67-77
11. Jeong Y.I., Prasad Y.R., Ohno T., Yoshikawa Y., Shibata N., Kato S., Takeuchi K., Takada K. Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine. J. Pharm. Pharmacol. 53:2001;1079-1085
12. Rudolph M., Klein S., Beckert T.E., Petereit H.U., Dressman J.B. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharm. Biopharm. 51:2001;183-190
13. Hu Z., Shimokawa T., Ohno T., Kimura G., Mawatari S.S., Kamitsuna M., Yoshikawa Y., Masuda S., Takada K. Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer, P-4135F. J. Drug Target. 7:1999;223-232
14. Clausen A.E., Bernkop-Schnürch A. In vitro evaluation of the permeation enhancing effect of thiolated polycarbophil. J. Pharm. Sci. 89:2000;1253-1261
15. Lamprecht A., Schafer U.F., Lehr C.M. Characterization of microcapsules by confocal laser scanning microscopy: structure, capsule wall composition and encapsulation rate. Eur. J. Pharm. Biopharm. 49:2000;1-9
16. Law S.L., Shih C.L. Characterization of calcitonin-containing liposome formulations for intranasal delivery. J. Microencapsul. 18:2001;211-221
17. Gitelman H.J. An improved automated procedure for determination of calcium in biochemical specimen. Anal. Biochem. 18:1967;521-531
18. K. Lehmann, W. Höss, Thermoplastic resin for enteric pharmaceutical coating, European patent EP 704, 207, July 25, 2001.
19. Chen X.Q., Yang Y.Y., Wang L., Chung T.S. Effects of inner water volume on the peculiar surface morphology of microspheres fabricated by double emulsion technique. J. Microencapsul. 18:2001;637-649
20. Tozaki H., Nishioka J., Komoike J., Okada N., Fujita T., Muranishi S., Kim S.I., Terashima H., Yamamoto A. Enhanced absorption of insulin and (Asu(1, 7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J. Pharm. Sci. 90:2001;89-97
21. Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 5:2000;77-85
22. Bernkop-Schnürch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 194:2000;1-13
23. Fukunaga M., Miller M.M., Deftos L.J. Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats. Horm. Metab. Res. 23:1991;166-167
24. Arien A., Goigoux C., Baquey C., Dupuy B. Study of in vitro and in vivo stability of liposomes loaded with calcitonin or indium in the gastrointestinal tract. Life Sci. 53:1993;1279-1290
25. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46:1994;547-552
26. Takeuchi H., Matsui Y., Yamamoto H., Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release. 86:2003;235-242
27. Sakuma S., Suzuki N., Sudo R., Hiwatari K., Kishida A., Akashi M. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int. J. Pharm. 239:2002;185-195
28. Sakuma S., Suzuki N., Kikuchi H., Hiwatari K., Arikawa K., Kishida A., Akashi M. Absorption enhancement of orally administered salmon calcitonin by polystyrene nanoparticles having poly(N-isopropylacry-lamide) branches on their surfaces. Int. J. Pharm. 158:1997;69-78
29. Morita T., Yamamoto A., Takakura Y., Hashida M., Sezaki H. Improvement of the pulmonary absorption of (Asu 1, 7)-eel calcitonin by various protease inhibitors in rats. Pharm. Res. 11:1994;909-913
30. Morimoto K., Miyazaki M., Kakemi M. Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int. J. Pharm. 113:1995;1-8
31. Tozaki H., Odoriba T., Iseki T., Taniguchi T., Fujita T., Murakami M., Muranishi S., Yamamoto A. Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J. Pharm. Pharmacol. 50:1998;913-920
32. Guggi D., Bernkop-Schnürch A. In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int. J. Pharm. 252:2003;187-196